Danielle Zerr

Adjunct Professor, Epidemiology
Professor, Pediatrics



MD <unknown>, Temple University, 1993
MPH Epidemiology, University of Washington, 1997
BA Biology, Brandeis University,



University of Washington Medical Center
Box 359300
Pediatrics, Division of Infectious Disease
Children's Hospital & Medical Ctr., Box 359300/MA.7.226
View Website »


Interim Division Chief and Professor of Pediatric Infectious Diseases, Affiliate Investigator at the Fred Hutchinson Cancer Research Center, and the Medical Director of Infection Prevention at Seattle Children’s Hospital

Research Interests

Dr. Zerr’s research interests lie in elucidating the epidemiology of healthcare-associated infectious diseases in children and immunocompromised hosts. A major area of focus is describing the natural history of human herpesvirus 6 and the clinical impact of viral reactivation in hematopoietic cell transplantation recipients. A second area of focus is describing the epidemiology of extended-spectrum cephalosporin-resistant Enterobacteriaceae in children and exploring strategies aimed at preventing and treating colonization and infection due to these organisms. She has successfully funded her research program since completing her training. Current grants support two projects: 1) a multicenter study describing the molecular epidemiology of antibiotic resistant Enterobacteriaceae in children, and 2) a randomized controlled trial of chlorhexidine gluconate bathing in children with cancer to determine whether the intervention reduces the incidence of central line associated bloodstream infections and acquisition of multi-drug resistant

Recent Publications (PubMed)

Reply to Are we certain that chlorhexidine gluconate bathing is not beneficial in deducing central line associated blood stream infections among children with cancer or undergoing hematopoietic stem cell transplantation?
(2021 May 4)
Zerr DM, Milstone AM, Adler AL, Dvorak CC, Fisher BT, Sung L

Line days as a determinant of central line-associated bloodstream infections in pediatric patients with tunneled femoral peripherally inserted central catheters.
(2021 Mar 6)
Pediatr Radiol
Koo KSH, Cooper AB, Monroe EJ, Reis J, Shivaram GM, Zerr DM

Comparative in vitro effectiveness of ceftolozane/tazobactam against pediatric gram-negative drug-resistant isolates.
(2021 Mar 1)
J Chemother
Kanwar N, Banerjee D, Harrison CJ, Newland JG, Qin X, Zerr DM, Zaoutis T, Selvarangan R

Prevalence of Health Care and Hospital Worker SARS-CoV-2 IgG Antibody in a Pediatric Hospital.
(2021 Mar)
Hosp Pediatr 11(3): e48-e53
Tokareva Y, Englund JA, Dickerson JA, Brown JC, Zerr DM, Walter E, Tsogoo A, Cappetto K, Valdez Gonzalez J, Strelitz B, Klein EJ

Pediatric research priorities in healthcare-associated infections and antimicrobial stewardship.
(2020 Nov 26)
Infect Control Hosp Epidemiol
Coffin SE, Abanyie F, Bryant K, Cantey J, Fiore A, Fritz S, Guzman-Cottrill J, Hersh AL, Huskins WC, Kociolek LK, Kronman M, Lautenbach E, Lee G, Linam M, Logan LK, Milstone A, Newland J, Nyquist AC, Palazzi DL, Patel S, Puopolo K, Reddy SC, Saiman L, Sandora T, Shane AL, Smith M, Tamma PD, Zaoutis T, Zerr D, Gerber JS, CDC Prevention Epicenters Program.

Show complete publication list

In the News

No news articles at this time.